2025-07-182026-03-312026-03-31false16590959FIDA THERAPY CLINIC LTD2026-05-20falseiso4217:GBPxbrli:pure165909592025-07-17165909592026-03-31165909592025-07-182026-03-31165909592025-07-16165909592025-07-17165909592025-07-172025-07-1716590959bus:SmallEntities2025-07-182026-03-3116590959bus:AuditExempt-NoAccountantsReport2025-07-182026-03-3116590959bus:FullAccounts2025-07-182026-03-3116590959bus:PrivateLimitedCompanyLtd2025-07-182026-03-3116590959core:WithinOneYear2026-03-3116590959core:AfterOneYear2026-03-3116590959core:WithinOneYear2025-07-1716590959core:AfterOneYear2025-07-1716590959core:ShareCapital2026-03-3116590959core:SharePremium2026-03-3116590959core:RevaluationReserve2026-03-3116590959core:OtherReservesSubtotal2026-03-3116590959core:RetainedEarningsAccumulatedLosses2026-03-3116590959core:ShareCapital2025-07-1716590959core:SharePremium2025-07-1716590959core:RevaluationReserve2025-07-1716590959core:OtherReservesSubtotal2025-07-1716590959core:RetainedEarningsAccumulatedLosses2025-07-1716590959core:LandBuildings2026-03-3116590959core:PlantMachinery2026-03-3116590959core:Vehicles2026-03-3116590959core:FurnitureFittings2026-03-3116590959core:OfficeEquipment2026-03-3116590959core:NetGoodwill2026-03-3116590959core:IntangibleAssetsOtherThanGoodwill2026-03-3116590959core:ListedExchangeTraded2026-03-3116590959core:UnlistedNon-exchangeTraded2026-03-3116590959core:LandBuildings2025-07-1716590959core:PlantMachinery2025-07-1716590959core:Vehicles2025-07-1716590959core:FurnitureFittings2025-07-1716590959core:OfficeEquipment2025-07-1716590959core:NetGoodwill2025-07-1716590959core:IntangibleAssetsOtherThanGoodwill2025-07-1716590959core:ListedExchangeTraded2025-07-1716590959core:UnlistedNon-exchangeTraded2025-07-1716590959core:LandBuildings2025-07-182026-03-3116590959core:PlantMachinery2025-07-182026-03-3116590959core:Vehicles2025-07-182026-03-3116590959core:FurnitureFittings2025-07-182026-03-3116590959core:OfficeEquipment2025-07-182026-03-3116590959core:NetGoodwill2025-07-182026-03-3116590959core:IntangibleAssetsOtherThanGoodwill2025-07-182026-03-3116590959core:ListedExchangeTraded2025-07-182026-03-3116590959core:UnlistedNon-exchangeTraded2025-07-182026-03-3116590959core:MoreThanFiveYears2025-07-182026-03-3116590959core:Non-currentFinancialInstruments2026-03-3116590959core:Non-currentFinancialInstruments2025-07-1716590959dpl:CostSales2025-07-182026-03-3116590959dpl:DistributionCosts2025-07-182026-03-3116590959core:LandBuildings2025-07-182026-03-3116590959core:PlantMachinery2025-07-182026-03-3116590959core:Vehicles2025-07-182026-03-3116590959core:FurnitureFittings2025-07-182026-03-3116590959core:OfficeEquipment2025-07-182026-03-3116590959dpl:AdministrativeExpenses2025-07-182026-03-3116590959core:NetGoodwill2025-07-182026-03-3116590959core:IntangibleAssetsOtherThanGoodwill2025-07-182026-03-3116590959dpl:GroupUndertakings2025-07-182026-03-3116590959dpl:ParticipatingInterests2025-07-182026-03-3116590959dpl:GroupUndertakingscore:ListedExchangeTraded2025-07-182026-03-3116590959core:ListedExchangeTraded2025-07-182026-03-3116590959dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-07-182026-03-3116590959core:UnlistedNon-exchangeTraded2025-07-182026-03-3116590959dpl:CostSales2025-07-172025-07-1716590959dpl:DistributionCosts2025-07-172025-07-1716590959core:LandBuildings2025-07-172025-07-1716590959core:PlantMachinery2025-07-172025-07-1716590959core:Vehicles2025-07-172025-07-1716590959core:FurnitureFittings2025-07-172025-07-1716590959core:OfficeEquipment2025-07-172025-07-1716590959dpl:AdministrativeExpenses2025-07-172025-07-1716590959core:NetGoodwill2025-07-172025-07-1716590959core:IntangibleAssetsOtherThanGoodwill2025-07-172025-07-1716590959dpl:GroupUndertakings2025-07-172025-07-1716590959dpl:ParticipatingInterests2025-07-172025-07-1716590959dpl:GroupUndertakingscore:ListedExchangeTraded2025-07-172025-07-1716590959core:ListedExchangeTraded2025-07-172025-07-1716590959dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-07-172025-07-1716590959core:UnlistedNon-exchangeTraded2025-07-172025-07-1716590959core:NetGoodwill2026-03-3116590959core:IntangibleAssetsOtherThanGoodwill2026-03-3116590959core:LandBuildings2026-03-3116590959core:PlantMachinery2026-03-3116590959core:Vehicles2026-03-3116590959core:FurnitureFittings2026-03-3116590959core:OfficeEquipment2026-03-3116590959core:AfterOneYear2026-03-3116590959core:WithinOneYear2026-03-3116590959core:ListedExchangeTraded2026-03-3116590959core:UnlistedNon-exchangeTraded2026-03-3116590959core:ShareCapital2026-03-3116590959core:SharePremium2026-03-3116590959core:RevaluationReserve2026-03-3116590959core:OtherReservesSubtotal2026-03-3116590959core:RetainedEarningsAccumulatedLosses2026-03-3116590959core:NetGoodwill2025-07-1716590959core:IntangibleAssetsOtherThanGoodwill2025-07-1716590959core:LandBuildings2025-07-1716590959core:PlantMachinery2025-07-1716590959core:Vehicles2025-07-1716590959core:FurnitureFittings2025-07-1716590959core:OfficeEquipment2025-07-1716590959core:AfterOneYear2025-07-1716590959core:WithinOneYear2025-07-1716590959core:ListedExchangeTraded2025-07-1716590959core:UnlistedNon-exchangeTraded2025-07-1716590959core:ShareCapital2025-07-1716590959core:SharePremium2025-07-1716590959core:RevaluationReserve2025-07-1716590959core:OtherReservesSubtotal2025-07-1716590959core:RetainedEarningsAccumulatedLosses2025-07-1716590959core:NetGoodwill2025-07-1616590959core:IntangibleAssetsOtherThanGoodwill2025-07-1616590959core:LandBuildings2025-07-1616590959core:PlantMachinery2025-07-1616590959core:Vehicles2025-07-1616590959core:FurnitureFittings2025-07-1616590959core:OfficeEquipment2025-07-1616590959core:AfterOneYear2025-07-1616590959core:WithinOneYear2025-07-1616590959core:ListedExchangeTraded2025-07-1616590959core:UnlistedNon-exchangeTraded2025-07-1616590959core:ShareCapital2025-07-1616590959core:SharePremium2025-07-1616590959core:RevaluationReserve2025-07-1616590959core:OtherReservesSubtotal2025-07-1616590959core:RetainedEarningsAccumulatedLosses2025-07-1616590959core:AfterOneYear2025-07-182026-03-3116590959core:WithinOneYear2025-07-182026-03-3116590959core:Non-currentFinancialInstrumentscore:CostValuation2025-07-182026-03-3116590959core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-07-182026-03-3116590959core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-07-182026-03-3116590959core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-07-182026-03-3116590959core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-07-182026-03-3116590959core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-07-182026-03-3116590959core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-07-182026-03-3116590959core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-07-182026-03-3116590959core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-07-182026-03-3116590959core:Non-currentFinancialInstrumentscore:CostValuation2026-03-3116590959core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-03-3116590959core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-03-3116590959core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-03-3116590959core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-03-3116590959core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-03-3116590959core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-03-3116590959core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-03-3116590959core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-03-3116590959core:Non-currentFinancialInstrumentscore:CostValuation2025-07-1716590959core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-07-1716590959core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-07-1716590959core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-07-1716590959core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-07-1716590959core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-07-1716590959core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-07-1716590959core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-07-1716590959core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-07-1716590959bus:Director12025-07-182026-03-3116590959bus:Director22025-07-182026-03-31

FIDA THERAPY CLINIC LTD

Registered Number
16590959
(England and Wales)

Unaudited Financial Statements for the Period ended
31 March 2026

FIDA THERAPY CLINIC LTD
Company Information
for the period from 18 July 2025 to 31 March 2026

Directors

FIDA, Saqiba
ULHAQ, Inam

Registered Address

110 Quinton Road West
Quinton
Birmingham
B32 2RH

Registered Number

16590959 (England and Wales)
FIDA THERAPY CLINIC LTD
Balance Sheet as at
31 March 2026

Notes

2026

£

£

Fixed assets
Tangible assets33,371
3,371
Current assets
Cash at bank and on hand7,250
7,250
Creditors amounts falling due within one year4(5,131)
Net current assets (liabilities)2,119
Total assets less current liabilities5,490
Net assets5,490
Capital and reserves
Called up share capital1
Profit and loss account5,489
Shareholders' funds5,490
The financial statements were approved and authorised for issue by the Board of Directors on 20 May 2026, and are signed on its behalf by:
FIDA, Saqiba
Director
Registered Company No. 16590959
FIDA THERAPY CLINIC LTD
Notes to the Financial Statements
for the period ended 31 March 2026

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Going concern
After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
2.Average number of employees

2026
Average number of employees during the year1
3.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
Additions4,1494,149
At 31 March 264,1494,149
Depreciation and impairment
Charge for year778778
At 31 March 26778778
Net book value
At 31 March 263,3713,371
At 17 July 25--
4.Creditors: amounts due within one year

2026

£
Taxation and social security497
Other creditors3,884
Accrued liabilities and deferred income750
Total5,131
5.Directors advances, credits and guarantees
At the reporting date, included in the other creditors is an amount of £3,884 due to director of the company.
6.Share capital
1 Ordinary shares of £1 each were allocated and fully paid for cash at par during the period.